Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases.The company’s pipeline products include ABX464, ABX544 and ABX196.
Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora.Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection.
The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.
Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
The ePRO, ePatient Diaries, and eCOA market in South and Central America is expected to grow from US$ 90.3 million in 2021 to US$ 229.0 million by 2028; it is estimated to grow at a CAGR of 14.2% from 2021 to 2028. Patient centricity means designing a treatment, clinical trial, or other health solution centered around the patient. Creating...
Free Fatty Acid Receptor 1 - Drugs In Development, 2021 Summary According to the recently published report ’Free Fatty Acid Receptor 1 - Drugs In Development, 2021’; Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 18 molecules. Out...
Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies...
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs.The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The...
The global Micropump market is expected to reach US$ 5,172.86 million in 2028 from as estimated value of US$ 1,553.01 million in 2021. The market is likely to grow with a CAGR of 18.8% from 2021-2028. The growth of the market is due to increasing demand for micropumps in medical device industry, and improved accuracy compared to traditional...
The global particle size analysis market reached a value of US$ 351.7 Million in 2020. Looking forward, the analyst expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different...
Executive Summary Global Hexamethyldisilazane Market was valued at USD 202.32 Million and xx Kilotonne by volume in the year 2020. Hexamethyldisilane (HMDS) is an organosilicon compound used as a reagent or precursor to bases and is primarily used as a silylating agent in the process of manufacturing pharmaceutical drugs...
The global microplate systems market size is projected to reach USD 1,170 million by 2026 from USD 927 million in 2021, at a CAGR of 4.8% from 2021 to 2026. Growth in this market is driven by the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, and the growing prevalence of diseases Microplate...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.